Predictors of Hypocalcemia Induced by Denosumab in Patients with Bone Metastases: A Prospective Cohort Study
Description: Hypocalcemia is the most common major adverse event in patients with bone metastasis receiving denosumab. In the present prospective study, we aimed to identify the risk factors of hypocalcemia. Although all patients received prophylactic administration (ALF: 1.0 ug and Ca: 600mg), 21.4 % and 2.4 % patients developed Grade1 and Grade2 hypocalcemia, respectively. It is possible that severe hypocalcemia was mitigated by oral supplementation. We also revealed that bone turnover markers are potentially useful for prediction of hypocalcemia following denosumab treatment in patients with bone metastasis. Routine measurement of serum calcium concentrations following denosumab is recommended for patients with high bone turnover for timely detection and early treatment initiation.
Amount: ¥1,430,000
Funding type: fellowship
Funder scheme: Grant-in-Aid for Young Scientists (B)
Start date: 2017-04-01
End date: 2020-03-31
Investigator: Koji Ishikawa
Institution: Showa University
Funded outputs count: 11
Funder award ID: 17K18114
OpenAlex ID: G6487973904